Abstract
This review summarises the patent and primary literature relating to gene therapy for HIV infection over the last year and comments on treatments under pre-clinical evaluation or in Phase I and II clinical trials. There is relatively little activity as yet in the clinical trial arena and there have been few major innovations in gene therapy approaches over this period. Hanging over this field, as in other areas of gene therapy, is the controversy over patenting of ex vivo gene therapy and doubts regarding the utility of certain vectors such as adeno-associated virus (AAV).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
